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OBJECTIVES: Tumor-associated macrophages have been implicated in promoting tumor growth, progression and
metastasis. However, the activated phenotype (M1 or M2) of tumor-associated macrophages remains unknown in
solid tumors. Therefore, this study examined the density and prognostic significance of M2-polarized tumor-
associated macrophages in lung adenocarcinoma.
METHODS: Tumor specimens from 65 lung adenocarcinoma patients were assessed by ELISA for Th1/Th2 cytokine
concentrations. The activated phenotype (M1 or M2) of tumor-associated macrophages was determined utilizing
immunofluorescence staining. Additionally, to evaluate lymphangiogenesis, peritumoral lymphatic microvessel
density was measured using D2-40. The correlation between tumor-associated macrophage subtype and overall
patient survival was analyzed using the Kaplan-Meier method and compared using the log-rank test.
RESULTS: A shift toward Th2 cytokine expression was detected within lung adenocarcinoma microenvironments.
Approximately 79.71¡16.27% of tumor-associated macrophages were M2 polarized; the remaining 20.35¡5.31%
were M1 polarized. The infiltration of M2-polarized macrophages was significantly associated with P-TNM staging
and lymph node metastasis. The peritumoral lymphatic microvessel density was significantly higher in the high M2-
polarized tumor-associated macrophage group than in the low M2-polarized tumor-associated macrophage group.
A significant difference in overall patient survival was detected not only between patients with tumors with high
and low macrophage counts but also between patients with tumors with high and low counts of M2-polarized
macrophages.
CONCLUSION: Tumor-associated macrophages in lung adenocarcinoma have an M2-polarized subtype and are
associated with poor prognoses, perhaps resulting from accelerated lymphangiogenesis and lymph node metastasis.
KEYWORDS: M2-polarized macrophages; Tumor-associated macrophages; Lymphangiogenesis; Lung
adenocarcinoma; Prognosis.
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INTRODUCTION
Recently, compelling evidence has emerged that macro-
phages infiltrating the tumor microenvironment, also known
as tumor-associated macrophages (TAMs), promote pro-
cesses such as angiogenesis, lymphangiogenesis, tumor
growth and progression in solid tumors.1,2 In addition to
their protumoral effects on lung adenocarcinoma, the role of
TAMs in promoting tumors is supported by clinical studies
that identified a correlation between high macrophage
numbers in tumor tissues and poor patient prognoses.3-5
However, the mechanisms underlying TAM functional
changes within tumor microenvironments remain unknown;
one potential cause is the altered polarization of TAMs with
associated changes in their activated phenotypes.6
There are at least two different subpopulations of activated
macrophages within tumor microenvironments. The first
type, known as classically activated macrophages (M1
macrophages), are activated by lipopolysaccharides (LPS) or
by double signals from interferon (IFN)-c and tumor necrosis
factor-a (TNF-a). M1-polarized macrophages exhibit an
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IL-12high, IL-23high, IL-10low phenotype and produce TNF-a
and nitric oxide (NO); they are potent effector cells that kill
microorganisms and tumor cells.7,8 The second type of
macrophages is known as alternatively activated macro-
phages (M2 macrophages). Exposure to IL-4, IL-13, vitamin
D3, glucocorticoids or transforming growth factor-b (TGF-b)
decreases macrophage antigen-presenting capability and up-
regulates the expression of macrophage mannose receptors
(MMR, also known as CD206), scavenger receptors (SR-A,
also known as CD204), CD163, dectin-1 and DC-SIGN.9 M2-
polarized macrophages exhibit an IL-12low, IL-23low, IL-10high
phenotype and play an important role in stroma formation,
tissue repair, tumor growth, angiogenesis and immunosup-
pression.10,11 Although several studies throughout the past
decade have suggested that TAMs exhibit a polarized M2
phenotype,12-14 limited reports describing the polarization of
activated TAMs (such as M1 and M2) within tumor
microenvironments have only recently been published.15-18
Lymphangiogenesis is considered to be an initial and
necessary event for lymphatic and regional lymph node
metastasis.19 A number of studies have demonstrated
lymphatic microvessel density (LMVD) to be an independent
prognostic factor in solid tumors.20-23 Additionally, several
studies have shown that TAMs contribute to lymphangiogen-
esis and lymphatic vessel invasion in malignant tumors.24,25
However, as TAMs are heterogeneous in different tumor
microenvironments and have multiple activated phenotypes,
further investigations are necessary to clarify whether all
TAMs or only M2-polarized TAMs correlate with lymphan-
giogenesis and poor prognosis in solid tumors.
Here, we investigated the density of infiltrating M2-
polarized TAMs and the association between M2-polarized
TAMs, lymphangiogenesis, and prognosis. We found that
TAMs in lung adenocarcinoma exhibit a M2-polarized
subtype and are associated with poor prognosis, perhaps
as a result of lymphatic metastasis.
MATERIALS AND METHODS
Ethics statement
This study was approved by the Ethics Committee of
Wuhan General Hospital, Guangzhou Command of the
People’s Liberation Army. Written informed consent was
obtained from all patients.
Patients and tissue samples
A total of 65 patients with lung adenocarcinoma who
underwent either lobectomy or pneumonectomy at Wuhan
General Hospital were included in the study. The study
group was composed of 38 men and 27 women with a mean
age of 51.5 years (age range: 32-76 years). The patients
underwent tumor resection from 2003 to 2006. None of the
patients had received any preoperative chemotherapy or
radiotherapy. The lesions of each patient were classified into
stages according to the UICC 2010 pTNM classification
scheme (7th edition); stage I, II, III, and IV lesions were
present in 12, 27, 24, and 2 patients, respectively.
Histologically, 16 tumors were graded as well-differentiated
adenocarcinoma, 20 as moderately differentiated, and 29 as
poorly differentiated. Lymph node metastasis occurred in
35 patients; no metastatic lymph nodes were observed in the
remaining 30 patients. Follow-up visits were conducted and
outcomes were recorded for all patients. A total of 20
patients with benign lung lesions, including six cases of
tuberculomas, six cases of inflammatory pseudotumors, five
cases of hamartomas and three cases of lung cysts, were also
included in this study. The clinicopathologic parameters of
the lung adenocarcinoma patients are shown in Table 1.
ELISA
Fresh human lung adenocarcinoma tissues and benign
lung lesions were obtained from surgical specimens for the
detection of Th1/Th2 cytokines by ELISA. Briefly, the
specimens were rinsed three times in phosphate-buffered
saline (PBS). Next, 1 g of each tissue sample was homo-
genized in 1 ml of PBS. Tissue homogenates were then
centrifuged at 12,000 g for 1 min at 25 C˚. After centrifugation,
the supernatants were collected for further analysis. Cytokine
production was quantified by cytokine-specific ELISA.
Human IFN-c, IL-12, IL-4, and IL-10 (Biosource, Camarillo,
CA, USA) ELISA kits were utilized; all procedures were
performed according to the manufacturer’s instructions.
Sample absorbances were determined using an ELISA plate
reader (Dynatech, Chantilly, VA, USA).
Immunofluorescence staining
For the simultaneous visualization of CD68 and MMR or
CD68 and inducible nitric oxide synthase (iNOS) on the same
tissue section, double-label immunofluorescence staining
was performed. The tumor tissues were acetone-fixed at
4 C˚ and then cut into 10-mm frozen sections. After being
rinsed three times in PBS, the slides were treated with 3%
H2O2 to inactivate endogenous peroxidases and then with
normal goat serum to block nonspecific binding sites. Next,
slides were immunostained using a monoclonal mouse anti-
human CD68 antibody (15100; Zhongshan Company, Beijing,
China). Slides were also stained with rabbit anti-human
MMR antibodies (15200; BioLegand, San Diego, CA, USA) or
rabbit anti-human iNOS antibodies (15200; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). All slides were
incubated overnight at 4 C˚. Next, the slides were rinsed
three times in PBS and incubated with TRITC-conjugated
goat anti-mouse IgG for 30 min and then with FITC-
conjugated goat anti-rabbit IgG for 30 min. Nuclei were
counterstained with 49-6-diamidino-2-phenylindole (DAPI)
for 5 min. All slides were examined under a laser confocal
microscope (Leica TCS SP5, Leica, German) fitted with TRITC
(red fluorescence) and FITC (green fluorescence) filters. The
excitation wavelength for FITC was 488 nm; the excitation
wavelength for TRITC was 568 nm. Red CD68-positive
fluorescence was located in the cytoplasm, and green
MMR-positive fluorescence was located at the cell membrane
and in the cytoplasm. However, green iNOS-positive
fluorescence was only observed in the cytoplasm. If CD68
and MMR or CD68 and iNOS were coexpressed, the
fluorescence was yellow. All nuclei were blue.
Immunohistochemistry
To evaluate LMVD, D2-40 was used as the immunohis-
tochemical marker for lymphatic endothelial cells (LECs).26
Resected tissue specimens were fixed in formalin,
embedded in paraffin, and cut into 5-mm serial sections.
Next, these sections were deparaffinized in xylene and
rehydrated with solutions of graded alcohol and deionized
water. The slides were immunostained with the mouse
monoclonal antibody D2-40 (15200; Signet Laboratories,
Dedham, MA, USA) overnight at 4 C˚. Next, the slides were
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exposed to a biotinylated secondary antibody for 20 min
and then treated with streptavidin peroxidase. For color
development, the slides were stained with 3, 39diamino-
benzidine (DAB). Hematoxylin and eosin (H&E) were used
as a counterstain. A reddish-brown precipitate in the
cytoplasm of LECs indicated a positive reaction.
After the immunostained sections were scanned at low
magnification (6100), the regions with the greatest numbers
of distinctly stained lymphatic foci (hot spots) were deter-
mined simultaneously by two different observers. Then, two
observers blinded to the tumor status or the stains used
independently counted the slides for LMVD staining under
400x magnification (0.03 mm2 field) in three regions. An
intratumoral compartment was identified as the area
encompassing the cancerous tissue in the H&E sections. A
peritumoral compartment was defined as a 1-mm-wide band
surrounding the intratumoral compartment that included the
edge of the tumor and just outside the tumor. Single
immunoreactive endothelial cells and endothelial cell clus-
ters separate from other microvessels were counted as vessels
according to previously used procedures.24
Statistical analysis
The numbers of M1- or M2-polarized TAMs and
intratumoral LMVD and peritumoral LMVD are expressed
as the mean¡SD. Statistical differences between the means
were analyzed using the independent samples t-test. Rates
were compared using a x2 test. The relationship between
TAM counts and LMVD was assessed using the Spearman
correlation test. On the basis of TAM or M2-polarized TAM
count, patients were classified into two groups, and the
overall survival rate was then compared between the high
and low groups, respectively. Overall survival time was
calculated from the date of surgery until death or, if the
patient was still alive, until the last follow-up visit. Death
from any cause was considered in the calculations of overall
survival. Two overall survival rates were calculated by the
Kaplan-Meier method and compared using the log-rank
test. Each prognostic factor was evaluated with regard to
survival in a multivariate analysis using a Cox proportional
hazards regression model. A p-value of ,0.05 was con-
sidered statistically significant. All statistical analyses were
performed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Th2 shift in lung adenocarcinoma
To detect Th1/Th2 cytokines in the microenvironment of
lung adenocarcinoma, we obtained fresh lung tumor tissues
and benign lung lesions from surgical resections and
assessed the expression of the Th1 cytokines IFN-c and IL-
12 and the Th2 cytokines IL-4 and IL-10 in tissue
homogenates using a cytokine-specific ELISA. As shown
in Figure 1, IFN-c and IL-12 expression was lower in fresh
Table 1 - The relationships between TAM, M1- or M2-polarized TAM counts and clinicopathologic features (x¡ s).
Clinicopathologic features Cases TAMs p-value M1-polarized TAMs p-value M2-polarized TAMs p-value
Gender
Male 38 104.19¡15.93 0.712 21.15¡6.11 0.948 83.04¡12.70 0.903
Female 27 103.07¡15.74 20.61¡5.73 82.15¡11.26
Age (yrs.)
$55 34 105.45¡18.96 0.895 21.29¡5.10 0.705 84.84¡12.04 0.681
,55 31 101.88¡14.11 20.58¡6.26 82.00¡10.61
Differentiation
Well-to-moderate 36 103.17¡15.15 0.984 20.63¡6.96 0.157 82.23¡10.43 0.645
Poor 29 103.98¡11.67 20.80¡6.16 82.87¡10.17
Lymph node metastasis
Positive 35 120.44¡35.83 0.042* 24.09¡4.56 0.882 95.99¡15.60 0.003*
Negative 30 94.26¡14.52 18.85¡7.27 70.26¡12.16
pTNM staging
I+II 39 96.38¡21.55 0.037* 20.31¡4.71 0.431 76.81¡10.32 0.029*
III+IV 26 115.49¡30.94 23.45¡5.35 92.05¡18.14
*Statistically significant.
Figure 1 - Th1/Th2 cytokine expression in fresh lung adenocarcinoma tissue and benign lung lesion homogenates (pg/ml). Fresh lung
adenocarcinoma homogenates contained significantly more IL-4 and IL-10 than benign lung lesion homogenates. * p,0.01.
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lung adenocarcinoma homogenates than in benign lung
lesion homogenates. However, fresh lung adenocarcinoma
samples contained significantly more Th2 cytokines than
benign lung lesion samples. IL-10 was the predominant Th2
cytokine present in the lung adenocarcinoma samples.
M2-polarized macrophages in lung
adenocarcinoma
To identify and quantify the infiltrated TAMs associated
with the M1 or M2 phenotype, we utilized anti-iNOS, anti-
MMR, and anti-CD68 antibodies for immunofluorescence
staining. CD68-positive macrophages were detected in
varying concentrations in all 65 lung adenocarcinoma cases
and in all 20 benign lung lesion samples. In the lung
adenocarcinoma samples, CD68-positive TAMs were pre-
dominately located in the peritumoral stroma and tumor
tissues, e.g., in the lumen of the lung adenocarcinoma; in
particular, TAMs were observed along the invasive tumor
front. MMR-positive signals predominately colocalized in
macrophages, but iNOS expression was detected in both
lung tumor cells and TAMs. M1-polarized TAMs were
defined as CD68+iNOS+, whereas M2-polarized TAMs were
distinguished by the expression of CD68 and MMR.15 M1-
and M2-polarized TAMs were detected in each of the 65
lung adenocarcinoma tissue samples. Overall, the percen-
tage of CD68+MMR+ TAMs was 79.71¡16.27% (Figure
2A), and the percentage of CD68+iNOS+ TAMs was
20.35¡5.31% (Figure 2B). CD68 and iNOS coexpression
was observed in 100% of the benign lung lesion samples; the
percentage of CD68+iNOS+ TAMs was 89.5%.
The correlation of M2-polarized TAMs with
clinicopathologic features
Table 1 also depicts the correlations between TAMs, M1-
or M2-polarized TAMs and clinicopathologic features. TAM
number and M2-polarized TAM number were significantly
associated with p-TNM staging (p= 0.037, 0.029) and lymph
node metastasis (p= 0.042, 0.003); however, these factors
were not associated with gender, age or tumor differentia-
tion. Interestingly, the number of M2-polarized TAMs was
more strongly correlated with lymph node metastasis than
the number of infiltrating CD68-positive TAMs. The
number of M1-polarized TAMs failed to correlate with
any of the clinicopathologic features included in this study.
The correlation of M2-polarized TAMs with
peritumoral LMVD
D2-40 positive lymph vessels were observed in each of the
65 lung adenocarcinoma examined. Lymphatic vessels with
the characteristic irregular morphology, empty lumina
without red blood cells, and thin endothelia were distinct
and stained strongly with D2-40 when present. Vessels
containing red blood cells did not stain positive with D2-40.
In lung adenocarcinoma samples, D2-40-positive vessels
were detected more frequently in the peritumoral stroma
(Figure 3A) than in the intratumoral compartment
(Figure 3B). The D2-40-positive peritumoral LMVD count
was 11.56¡10.73, which was higher than the D2-40-positive
intratumoral LMVD count (2.96¡1.15) (Figure 3C, p,0.01).
Because peritumoral LMVD is a significant prognostic
factor for non-small-cell lung cancer (NSCLC),27 we explored
the correlation between M2-polarized TAMs and peritumoral
LMVD. We divided all of the cases into two groups according
to their CD68 grade (cutoff value = 102); the low-TAM group
included 25 cases, and the high-TAM group was comprised
of 40 cases. There was a significant difference in peritumoral
LMVD between the two groups (p= 0.047). Next, we divided
all of the cases into two groups according to their levels of
CD68/MMR expression (cutoff values = 82): the low M2-
polarized TAM group (16 cases) and the high M2-polarized
TAM group (49 cases). The peritumoral LMVD was
significantly higher in the high M2-polarized TAM group
than in the low M2-polarized TAM group (p= 0.009). Lastly,
we divided all of the cases into two groups according to their
levels of CD68/iNOS expression: the low M1-polarized TAM
group (31 cases) and the high M1-polarized TAM group (34
cases). There was no significant difference in peritumoral
LMVD between the two groups.
The prognostic significance of M2-polarized TAMs
To assess the prognostic significance of M2-polarized
TAM infiltration, patients were first classified into two
groups based on their TAM count; patients in each group
were then further divided into two subgroups based on
their M2-polarized TAM count. . We used median values of
102 and 82 as the cutoff values for the TAM and M2-
polarized TAM counts, respectively. The median survival
times were 36 and 11 months for patients with TAM counts
of #102 and .102, respectively. The five-year survival rates
in the low TAM group and the high TAM group were 28.0%
Figure 2 - M2- and M1-polarized TAMs in lung adenocarcinoma. (A) The coexpression of CD68 and MMR in TAMs in human lung
adenocarcinoma sections. (B) The coexpression of CD68 and iNOS in TAMs in human lung adenocarcinoma sections.
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and 7.5%, respectively. Figure 4A depicts the difference in
the overall survival rates between the high-TAM-count
group and the low-TAM-count group (p,0.001). The
median survival times were 52 and 12 months for patients
with M2-polarized TAM counts of #82 and .82, respec-
tively. The five-year survival rates in the low M2-polarized
TAM group and the high M2-polarized TAM group were
37.5% and 8.2%, respectively; the overall survival rate was
significantly lower in the high M2-polarized TAM group
than in the low M2-polarized TAM group (p,0.001)
(Figure 4B).
Multivariate analysis
TAM count, M1-polarized TAM count, M2-polarized TAM
count, intratumoral LMVD, peritumoral LMVD, and other
factors, including gender, age, tumor differentiation, lymph
node metastasis, and P-TNM staging, were analyzed using
Cox proportional hazards regression models in all of the lung
adenocarcinoma patients. TAM count, M2-polarized TAM
count, peritumoral LMVD, lymph node metastasis, and
P-TNM staging were independent prognostic factors for
overall survival (Table 2).
DISCUSSION
Our data demonstrate that a shift toward the production of
Th2 cytokines, a factor that induces alternative macrophage
activation, occurs within the lung adenocarcinoma tumor
microenvironment. Under normal conditions, Th1/Th2
cytokines in the body are in a dynamic balance. When a
Th2 shift occurs, the immune system can become suppressed,
making the host more susceptible to microbial infections,
tumorigenesis and progression, allergic reactions, and graft
rejection reactions.28 Human NSCLC cells express a type-2
cytokine pattern both in situ and in vitro, which may play an
active immunoregulatory role in the lung cancer microenvir-
onment.29 In patients with several malignant tumors, includ-
ing lung tumors, a Th2 cytokine shift has been positively
correlated with the degree of malignancy.28,30 In our study,
IL-4 and IL-10 were detected in high amounts in lung
adenocarcinoma tissue homogenates.
Macrophages are plastic cells; for example, they can
switch between an activated M1 state and an activated M2
state depending upon specific signals within their micro-
environment. Because IL-4 is an activator of M2-polarized
macrophages and IL-10 is known to function to promote the
development of M2 macrophages from monocytes,31 the
cytokine signals required for M2 activation were abun-
dantly present within the microenvironment of the exam-
ined lung adenocarcinoma. Recently, Ohtaki et al. found
that IL-10 was significantly correlated with the number of
CD204-positive macrophages (M2 macrophages) within the
stroma of lung adenocarcinoma.32
M2-polarized TAMs were detected predominantly in
lung adenocarcinoma and were significantly associated
with p-TNM staging and lymph node metastasis. In a series
of reviews, Martinez et al. proposed that TAMs might
polarize toward an M2 phenotype.14 Hagemann et al.
demonstrated that when co-cultured, ovarian cancer cells
switched co-cultured macrophages to an M2 phenotype
similar to that of ovarian TAMs.15 Initially, macrophages in
solid ovarian tumors were identified by CD68 expression;
in serial sections, these macrophages also expressed SR-A.
Using flow cytometric analysis, these authors observed that
a large proportion of CD68(+) macrophages in samples of
ovarian cancer ascites were also positive for MMR
Figure 3 - Peritumoral (A) and intratumoral LMVD (B) in lung adenocarcinoma samples. D2-40-positive staining was detected in lymph
vessels by immunohistochemical staining (6400, SP method). The red arrow indicates the LMVD detected in lung tissues. (C) The LMVD
of lung adenocarcinoma tissues and adjacent peritumoral tissues. * p,0.01.
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(62.73¡16.27%) and SR-A (66.28¡4.31%). Further, co-
culturing of human primary ovarian cancer cells with
human macrophages increased macrophage MMR and SR-
A surface expression. In murine colon adenocarcinoma-38
and GL261 murine glioma, over 90% of tumor-infiltrating
myelomonocytoid cells were of the CD11b+ F4/80+ mono-
cyte/macrophage lineage. These cells also had a myeloid-
derived suppressor cell phenotype, as they suppressed the
proliferation of activated splenic CD8+ T cells and exhibited
a CD11b+ CD11c+ Gr-1low IL-4Ra+ phenotype. In addition,
tumor-infiltrating myelomonocytoid cells expressed higher
levels of MMR and lower levels of CXCL10, which are
alternative and classical macrophage activation markers,
respectively.33
In the present study, M1 and M2 macrophages coexisted
in the tumor microenvironment, which showed the hetero-
geneity of TAMs in lung adenocarcinoma. However, a
greater number of M2-polarized TAMs were detected than
M1-polarized TAMs. Further, M2-polarized TAMs were
more strongly correlated with lymph node metastasis than
were CD68-positive TAMs. These data suggest the impor-
tant role of M2-polarized TAMs in tumor progression and
metastasis.
Our study also showed that M2-polarized TAMs were
associated with poor prognosis in lung adenocarcinoma,
perhaps resulting from accelerated lymphangiogenesis and
lymph node metastasis. Because previous studies concern-
ing the relationship between TAM infiltration and clinical
outcome in various cancers did not describe TAM hetero-
geneity and presented contradicting conclusions, the
significance of macrophage infiltration in patient survival
has been controversial. Recently, several studies have
demonstrated that M2-polarized TAMs in gliomas,17 lung
adenocarcinoma,32 intrahepatic cholangiocarcinomas,34
and angioimmunoblastic T-cell lymphoma adenocar-
cinoma35 are associated with tumor progression and
prognosis. In the present study, we have also found M2-
polarized TAMs to be associated with poor prognosis in
lung adenocarcinoma patients. The patients with high M2-
polarized TAM counts exhibited poor survival. Our multi-
variate Cox proportional hazards analysis indicated that
M2-polarized TAM density was a useful prognostic marker
for overall survival in lung adenocarcinoma cases. Two
research papers previously reported that in patients with
extended survival, macrophages infiltrating the tumor
islets in NSCLC were predominantly of the M1 pheno-
type.36,37 These results appear to differ from our findings.
However, in our research, the types of lung cancer
involved were restricted to lung adenocarcinoma, not
NSCLC, which may be primarily responsible for the
conflicting findings.
Metastatic tumors that are spread through the blood or
lymphatic vessels occur in most forms of human cancer,
with peritumoral lymphangiogenesis and regional lymph
node metastasis often being the most important prognos-
tic factors for carcinoma patients.38 In addition to tumor
cells, TAMs and other inflammatory cells in the tumor
stroma can express VEGF-C and VEGF-D and promote
peritumoral lymphangiogenesis and lymph node metas-
tasis.24,25 Previously, we reported that alternatively
activated TAMs can induce peritumoral lymphangiogen-
esis in a murine Lewis lung adenocarcinoma model.39 In
the present study, for the first time, a positive correlation
between M2-polarized TAM count and peritumoral
LMVD, but not intratumoral LMVD, was found in
patients with lung adenocarcinoma. Interestingly, the
Figure 4 - Kaplan-Meier curves for overall survival by TAM count
(A) and M2-polarized TAM count (B) in patients with lung
adenocarcinoma. A shows the difference in the overall survival
rate between the high and the low TAM count groups (p,0.001).
B shows the difference in the overall survival rate between the
high and the low M2-polarized TAM groups (p,0.001).
Table 2 - Hazard ratios (HR), 95% confidence interval (CI)
and p-value for the 65 patients with lung
adenocarcinoma.
Factor p-value HR 95% CI
Gender 0.303 0.574 0.200-1.649
Age 0.393 1.317 0.700-2.480
Differentiation 0.670 1.175 0.558-2.476
Lymph node metastasis 0.011* 2.778 1.260-6.123
P-TNM staging 0.039* 3.021 1.055-8.649
TAM count 0.015* 3.602 1.279-10.142
M1-polarized TAMs count 0.860 0.881 0.214-3.628
M2-polarized TAMs count 0.031* 4.280 1.146-15.984
Intratumoral LMVD 0.327 1.189 0.841-1.679
Peritumoral LMVD 0.038* 1.073 1.004-1.147
*Statistically significant.
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LMVD in cases with high numbers of infiltrating
M2-polarized TAMs was significantly higher than in cases
with low numbers of M2-polarized TAMs. These data
suggest that in lung adenocarcinoma patients, M2-polar-
ized TAM infiltration is correlated with poor survival,
likely as a result of accelerated lymphangiogenesis and
lymph node metastasis.
Our data indicate that M2-polarized TAMs in lung
adenocarcinoma are a predictor of poor prognosis as a
result of their promotion of lymphangiogenesis and
lymphatic metastasis. Because M2-polarized TAMs appear
to play an important role in peritumoral lymphangiogenesis
and decreased survival in lung adenocarcinoma patients,
they represent a potential target for therapeutic interven-
tion. It is possible that the use of exogenous agents to switch
the phenotype of the TAMs from M2 to M1 during tumor
progression could decrease lymphatic metastasis and pro-
long lung adenocarcinoma patient survival.
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